-
EP3763360
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3763360
| EP3763360 - 17-HYDROXYPROGESTERONE ESTER-CONTAINING ORAL COMPOSITIONS AND RELATED METHODS [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 15.03.2024 Database last updated on 20.07.2024 | |
| Former | Examination is in progress Status updated on 20.07.2023 | ||
| Former | Request for examination was made Status updated on 16.07.2021 | ||
| Former | The application has been published Status updated on 11.12.2020 | Most recent event Tooltip | 15.03.2024 | Application deemed to be withdrawn | published on 17.04.2024 [2024/16] | Applicant(s) | For all designated states Lipocine Inc. 675 Arapeen Drive Suite 202 Salt Lake City UT 84108 / US | [2021/02] | Inventor(s) | 01 /
GILIYAR, Chandrashekar 3375 Edward Way Salt Lake City, UT 84124 / US | 02 /
VENKATESHWARAN, Srinivansan 1813 Laurelhurst Drive Salt Lake City, UT 84108 / US | 03 /
CHICKMATH, Basawaraj 4344 Muirfield Drive Apt. 20 Salt Lake City, UT 84124 / US | 04 /
NACHAEGARI, Satish Kumar 1923 East 4500 South Holladay, UT 84117 / US | 05 /
NACHIAPPAN, Chidambaram 8410 Handcart Circle Sandy, UT 84070 / US | [2021/02] | Representative(s) | Vossius & Partner Patentanwälte Rechtsanwälte mbB Siebertstrasse 3 81675 München / DE | [2021/02] | Application number, filing date | 20175435.5 | 27.07.2012 | [2021/02] | Priority number, date | US201113193571 | 28.07.2011 Original published format: US201113193571 | [2021/02] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP3763360 | Date: | 13.01.2021 | Language: | EN | [2021/02] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 11.12.2020 | Classification | IPC: | A61K9/48, A61K9/20, A61K31/57, A61K31/56, A61K47/30, A61P15/06 | [2021/02] | CPC: |
A61K31/57 (EP,US);
A61K47/10 (US);
A61K47/12 (US);
A61K47/14 (US);
A61K47/20 (US);
A61K47/22 (US);
A61K47/26 (US);
A61K47/32 (US);
A61K47/44 (US);
A61K8/63 (US);
A61K9/0053 (US);
A61K9/14 (US);
A61K9/145 (EP,US);
A61K9/1617 (EP,US);
A61K9/1623 (EP,US);
A61K9/1635 (EP,US);
A61K9/1641 (EP,US);
A61K9/1652 (EP,US);
A61K9/1676 (EP,US);
A61K9/2013 (US);
A61K9/2018 (EP,US);
A61K9/2031 (US);
A61K9/2054 (EP,US);
A61K9/2059 (EP,US);
A61K9/4841 (US);
A61K9/4858 (EP,US);
A61K9/4866 (EP,US);
A61P15/00 (EP);
A61P15/06 (EP);
A61P15/08 (EP);
A61P15/12 (EP);
A61P17/00 (EP);
A61P17/06 (EP);
A61P17/08 (EP);
A61P17/10 (EP);
A61P19/10 (EP);
A61P25/00 (EP);
A61P25/24 (EP);
A61P5/00 (EP);
A61P5/30 (EP);
A61P7/04 (EP);
A61P9/10 (EP);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/33] |
| Former [2021/02] | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR | Title | German: | 17-HYDROXYPROGESTERONESTERHALTIGE ORALE ZUSAMMENSETZUNGEN UND ZUGEHÖRIGE VERFAHREN | [2021/02] | English: | 17-HYDROXYPROGESTERONE ESTER-CONTAINING ORAL COMPOSITIONS AND RELATED METHODS | [2021/02] | French: | COMPOSITIONS ORALES CONTENANT UN ESTER DE 17-HYDROXYPROGESTÉRONE ET PROCÉDÉS S'Y RAPPORTANT | [2021/02] | Examination procedure | 13.07.2021 | Amendment by applicant (claims and/or description) | 13.07.2021 | Examination requested [2021/33] | 13.07.2021 | Date on which the examining division has become responsible | 19.07.2023 | Despatch of a communication from the examining division (Time limit: M04) | 30.11.2023 | Application deemed to be withdrawn, date of legal effect [2024/16] | 20.12.2023 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2024/16] | Parent application(s) Tooltip | EP12818254.0 / EP2736515 | Fees paid | Renewal fee | 19.06.2020 | Renewal fee patent year 03 | 19.06.2020 | Renewal fee patent year 04 | 19.06.2020 | Renewal fee patent year 05 | 19.06.2020 | Renewal fee patent year 06 | 19.06.2020 | Renewal fee patent year 07 | 19.06.2020 | Renewal fee patent year 08 | 19.06.2020 | Renewal fee patent year 09 | 29.11.2021 | Renewal fee patent year 10 | 27.07.2022 | Renewal fee patent year 11 | 27.07.2023 | Renewal fee patent year 12 | Penalty fee | Additional fee for renewal fee | 31.07.2021 | 10 M06 Fee paid on 29.11.2021 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [XY]WO0059482 (SCHERER CORP R P [US], et al) [X] 1,6,11,14 * page 1, line 1 - line 3 * * page 3, line 20 - page 4, line 17 * * page 7, line 3 - line 12 * * examples 1A-14A * * claim - * [Y] 15; | [XYI]CN1623550 (ZHANG WEI [CN]) [X] 1,5,6,10,12-14 * the whole document * [Y] 15 [I] 2-4,7-9,11; | [Y]US2008188829 (CREASY GEORGE [US]) [Y] 15 * paragraph [0015] - paragraph [0016] * * paragraph [0019] * * paragraph [0057] ** claim - * |